You are logged out -> Log in

Hereditary Research Laboratory

Research Platforms and Grants

 

 

 

Hearing Loss

Summary

The overall goal inhuman genetic research is to understand the biological function of normal genes, and how once perturbed, they lead to a diseased state. Errors in our genes, or mutations, often cause one of the most common sensory defects, the loss of hearing. Hereditary sensorineural hearing loss affects approximately 3% of the population in Palestine and can reach 15% in isolated communities. There are many sociological implications of hearing loss, including problems of isolation and loneliness for those losing their hearing later in life, and comparatively poor educational achievements, especially for those losing their hearing early in life.  The goal of this research project is to identify and understand the molecular basis of mutations in deafness genes in  the Palestinian deaf populations The identification of mutant genes in the Palestinian populations will allow for early intervention and aid the individuals affected.  Eventually the study of the genes causing deafness will allow us to learn how normal hearing functions.  Understanding the normal function of the genes, and the mutations that cause hearing loss, will enable investigators to suggest new means of treating sensorineural deafness. Therefore, these studies will lead to better diagnosis of inherited deafness and help improve the quality of life of deaf individuals in the Palestinian  populations.


 

Background Information and Justification

The name designated to our part of the world, "The Middle East, disguises the important differences within its limits.  For the past 5000 years, the eastern shores of the Mediterranean have seen the migrations of many different peoples who have come and stayed.  These distinct populations have lived in their own villages, relatively unaffected by the international trade routes which transverse the area.  Culturally, they were, and many still are, organized into tribes and large families, only few of which may populate a village.  Marriages have been arranged within the tribe, leading to a very high incidence of consanguineous marriages. Because of this region's unique characteristics, of diverse populations that have kept themselves quite isolated from each other, despite their geographic proximity, some serious public health issues of genetic origin  (ex. deafness and breast cancer) have been observed and carefully documented.  

Consanguinity, which is a nearly universal feature of traditional societies, greatly magnifies these genetic  diseases into serious public health problems. Paradoxically, consanguinity facilitates discovery of unknown genes of these diseases by providing a sufficient number of related affected individuals and their unaffected family members that is necessary for linkage analysis.  This proposal is the emerging field of the human  genome project.  More specifically, it deals with the molecular description and diagnosis of genetic hearing loss that have risen to a high frequencies within Palestinian populations in order to permit genetic counseling of potentially affected families and individuals.

Recent breakthrough developments in the area of human genetics and current advances in biotechnology have raised the urgent demand for laboratories which will specialize in implementing these methodologies for the benefit of general society.  The research proposal outlined here will enable a Palestinian investigator to interact and collaborate scientifically with Dr. Mary King Lab for the common good of the people.  The exchange  resources and research experience will benefit both laboratories and institutions, with the goal of improving the health of individuals from both areas.

Deafness is the most common form of sensory impairment in humans. Approximately 3 out of 1000 individuals is born deaf, while about 1 out of 10 is deaf or hard of hearing. Deafness accounts for a frequency that reaches 15% in certain geographic area in Palestine.  Hearing impairment can result  from a variety of injuries or diseases, and occur both in association with other symptoms in the form of syndromic deafness, or as an isolated finding, in the form of non-syndromic deafness.  Despite its prevalence in the human population, very little is known about the molecular events leading to  deafness and about the genes that control normal hearing. An understanding of this process will enable early diagnosis of hearing loss and thus provide a means to treat or cure this problem.

The first reports of genes involved in non-syndromic deafness have appeared recently, and so we now have the first opportunity to screen the human deaf population for mutations in these genes.  Myosin VI, an unconventional myosin, was isolated during a positional cloning approach to identify the gene encoded by the mouse recessive deafness mutation, Snell'swaltzer (sv). The human myosin VI (MYO6) cDNA has recently been cloned and characterized, and the genomic structure is currently being determined.  Myosin VIIA (MYO7A) was found to be defective in shaker-1 (sh1) mice, an autosomal recessive mutation characterized by deafness and vestibular dysfunction and in human Usher syndrome type 1B, an inherited disease characterized by deafness, vestibular dysfunction and retinitis pigmentosa.  Mutations in myosin VIIA were recently  reported in a human autosomal recessive deafness locus, DFNB2, and in small families with non-syndromic deafness.  Connexin 26(CX26) mutations were found in families exhibiting both autosomal and recessive forms of non-syndromic deafness.

The most recent deafness locus (DFNA1) to be cloned is diaphanous (DIA), found to be mutated in a Costa Rican kindred. The involvement of an unconventional myosin in both human and mouse deafness (myosin VIIA), the similarity of the human and mouse auditory  systems, and the existence of additional unidentified human deafness loci suggest that MYO6 will also be involved in human deafness.  The cloning of the human MYO6 cDNA makes it possible to determine if MYO6 is altered in human deafness disorder.  I  plan to perform mutation screening to identify MYO6 mutations in the human deaf population in Palestinian populations.  In addition, I will screen these families for mutations in MYO7A, CX26 and DIA using different techniques.  This field is expanding rapidly, and I expect more genes to be identified in the near future.  As these reports become available, I will incorporate these mutation screens in my future project.  This will increase the chances of finding mutations causing  deafness in the families.



Hereditary Hearing Loss

In a pilot study that we conducted at Human  Genetics Lab at Bethlehem University, we have studied about 50 different families with hearing impairment. Only 22% of these families harbored mutations in this gene, with 5 different mutations found in the population one of which, 35delG is responsible for about 50% of the cases with hearing loss attributed to this gene.

Work was done on a number of selected families that had more than two affected individuals and did not show any GJB2 mutations neither in the coding sequence nor in the upstream region.  The idea was to test possible linkage of hearing impairments in these families to some of the known deafness genes.  We could not establish any linkage in the screened families with any of the genes and loci that looked at. One Palestinian family under went a whole genome scan, in collaboration with the University of  Washington, Seattle, where a novel deafness locus has been found (DFNB28). Our efforts now focus on finding the gene responsible for deafness in this family as well as screening other Palestinian families for possible linkage to the same loci.

Funded: Fogarthy International Award (FIRCA pro gram-USA), 2000-2003



Expected benefits of Project

- Primary Beneficiaries. The primary beneficiaries of this research project will be the deaf and hearing impaired population of the West Bank and Gaza Strip.  Deafness is the  most common form of sensory impairment in humans. There are many sociological implications of hearing loss, including problems of isolation and loneliness for those losing their hearing later in life and comparatively poor educational achievements, especially for those losing their hearing early in life. In ours and most societies in the world, the ability to hear is the �normal� way of life, whereas those who have difficulty hearing must conform in order to succeed both socially and professionally in life. Despite its prevalence in the Palestinian  population very little is known about the molecular events leading to deafness and about the genes that control normal hearing. problem. Success in prevention through population screening and prenatal diagnosis largely hinges on an accurate knowledge of phenotype / genotype correlation and this project should provide such an understanding. It should be obvious, however, that the only realistic long term solution for deafness is the effective therapy through a detailed understanding of the molecular mechanisms, a challenge similar to that faced for many other genetic diseases in the whole World.

- While this project is going to concentrate on deafness, it will undoubtedly have considerable impact on the introduction of relevant techniques and molecular diagnostic to my research lab at Bethlehem university. The  lab is expected to constitute the missing link between these methodologies and its needed society value in the context  of training qualified manpower, data evaluation and quality control of clinical results. In addition, the lab will provide the frame work that this new information is used in the most responsible manner and according to the guidelines for genetic diagnosis and counseling. Bethlehem university has approved a new program in medical biotechnology. This research study will enrich both  teaching and laboratory capabilities of this program.

For more information

 

B-Thalasimia

 

A study of the spectrum of b-Thalasimia mutations in the West Bank revealed the presence of ten different b-globin mutations. The study involved 42 patients with B-thal major and 43 suspected carriers with Cooley's anemia. The IVS1.6 mutation predominated with a frequency of 52.8% and was almost invariably associated with chromosome haplotype VI. Seven other mutations (-30, FS5, IVS1.1, IVS1.110, N37, N39, IVS2.1), commonly found in the Mediterranean basin, occurred with frequency of 0.8% to 11.0%. In addition +G insertion in FS8/9 and N15 (a lesion previously found in Asian Indians and rarely found in the Mediterranean population) was demonstrated in two patients with haplotype I. The IVS1.6 homozygous patients were variable in their need for transfusion from dependent to independent phenotype. Characterization of the IVS1.6 variable phenotype is under way and may reveal further mutation in the b-globin cluster or other genetic modification.

 

Epidermolysis Bullosa Simplex (EBS)

Clinical and Genetic Features

Epidermolysis bullosa (EB) encompasses an heterogeneous group of hereditary disorders characterized by blistering of the skin upon exposure to mechanical stress. Although the most obvious signs of the disease are vesicles and bullae within the skin and mucous membranes, internal organs may also be involved (Fine et al, 2000).

EB is traditionally classified in three major groups according to the level of dermal-epidermal separation at the basement membrane (BM) zone. EB simplex (EBS) results from separation of the skin above the BM as a result of basal keratinocyte cytolysis; Junctional EB (JEB) is caused by blister formation within the BM above the lamina densa, while in dystrophic EB (DEB), blisters develop below the BM (Fine et al, 2000; Pulkinnen and Uitto, 1999).

EBS is considered to be the most frequent form of EB with an estimated prevalence of 1:20000 to 1:50000 (Nakano et al, 2000) Three major clinical subtypes have been recognized: Weber-Cockayne subtype mainly affecting the palms and soles; Koebner subtype characterized by a generalized distribution of blisters; and Dowling-Meara subtype presenting at birth with extensive and severe blistering often involving mucosae and nails (Irvine and McLean, 1999).

The molecular cause of EBS was elucidated about 10 years ago. Numerous studies in animal models and humans firmly established that most cases of EBS are caused by mutations in 2 genes encoding keratin 5 or 14 (Irvine and McLean, 1999; Uitto and Pulkinnen, 2001). These two keratin molecules form the bulk of the protein contents of basal keratinocytes and participate as obligatory heterodimers in the formation of the keratin intermediate filaments (KIF) cytoskeleton in these cells. Mutations in either one of the two basal keratin genes affect the ability of the keratin molecules to assemble into a filamentous network and consequently impair keratinocyte capacity to resist mechanical stress, leading to cytolysis and blister formation upon exposure of the skin to friction forces. Severity of the clinical phenotype seems to correlate with the degree to which cellular resilience is compromised (Irvine and McLean, 1999).

Despite marked advances in our understanding of EBS during the last decade, little is currently known about the molecular genetics of the disease in geographic areas outside the US and Europe. Our research study was performed to elucidate the clinical and genetic features of a cohort of Palestinian families affected with EBS.

 

Pharma

"Pharmacogenic gene delivery and gene therapy of Restenosis "

Antisense oligodeoxnucleotides (ODN) are small stretches that have shown the ability to inhibit gene expression. Therefore, they are promising candidates for the treatment of various diseases. However, because of poor stability in biological fluids and weak intracellular penetration their use in living systems is prohibited. Aiming to increase their stability, phosphorothioated ODNs were developed. However, non-sequence specific interactions with cellular proteins and toxicity still remain a major disadvantage for their use. For increasing their uptake ODNs have been covalently conjugated or condensate to cationic peptides, entrapped into pH-sensitive liposomes or cationic lipid-mediators and colloidal no particle.

Our biodegradable, biocompatible poly (DL-lactide-co-glycolide) based sub-micron sustained action formulations would offer efficient intracellular localization and prolonged uptake of antisene ODN. PLGA based double emulsion system and the solvent evaporation techniques were used to incorporate different ODNs. Due to lack of mRNA overlapping, for each of rat PDGFR-ß and human PDGFR-ß two anti-sense along with their scrambled sequences were designed. Fully and partially phosphorothioated ODNs were used in this study. The formulations were prepared and characterized for loading efficiency (80%), sustained release profile (over a month), size and morphology (300 nm). The bioactivity of the encapsulated ODNs was investigated by in-vitro transfection of rat smooth muscle (SMC) and ZnR5 cells (expressing human PDGFR-ß). The biological activity of the ODN-NPs was evaluated by assessment of cell growth inhibition and receptor down regulation.

It is well known that vascular smooth muscle cells (VSMC) proliferation and migration play a major role in neointima formation (i.e. restenosis). Both proliferation and migration of VSMC are induced after percutaneous transluminal coronary angioplasty (PTCA). Recent reports based on in vitro studies and animal models highlight the possible importance of PDGFR-ß/PDGF and avß5 integrals transudation pathways in mediating this process. Preliminary studies in our lab have shown that the PDGFR-ß/PDGF inhibition reduces VSMC proliferation by 35%, however other studies have implicated the OPN/avß3 pathway in VSMC proliferation. In this proposal, a novel delivery technique with antisense oligonucleotides will be utilized for dual inhibition of both the PDGFR-ß/PDGF and the OPN/avß3 pathways. The main goal is to achieve a stable and sustainable VSMC proliferation inhibition. The experimentation in this research will facilitate the understanding of the bimolecular processes involved in neointima formation. It will have great impact on the future designing of new therapies of coronary diseases.

More information
(Power Point Presentation)

 

Computational Genomics

Middle East Regional Genome Endeavor (MERGE)

Computational Genomics is a new branch of science that bridges biology and genetics with information and computer sciences. An important momentum for this development is provided by the world Human Genome Project. . The Weizmann Institute and the Hebrew University of Jerusalem now harbor a national laboratory for Genome technologies. Its capacities, combined with the collaborative spirit of the Middle East Regional Genome Endeavor (MERGE), allowed us to create new knowledge and distribute novel and crucial genome-related information among the collaborating parties. Much of the future progress in biotechnology, medicine and agriculture is depend on innovative and computer-intensive whole-genome methods for studying many genes in parallel. This allows physicians and biotechnology developers to create and utilize tools for studying, diagnosing and eventually treating inherited diseases, as well as inherited and somatic mutations that underlie malignancy, and congenital risks to develop such diseases. Equally important, Genome technologies allow a frontal attack on the major public health problems – common multigenic diseases such as hypertension, diabetes and heart failure. Genome technologies form the basis for novel diagnostic methods that will allow one to "fingerprint" a very large number of traits in an individual. Such methods are particularly adept to study the highly diverse populations of region, with their variable, distinct origins and, sometimes high, consanguinity rate. The same technologies made it possible to do the typing of pathogens, as well as normal and aberrant tissues. Finally, the agriculture of this new millennium will be strongly dependent on Genome infrastructures, and our strong link through MERGE forms the needed network that is provides the necessary information that all connected parties can benefit from.

Bethlehem University Foundation
Email: brds@bufusa.org
Phone: +1-240-241-4381
Fax: +1-240-553-7691
Beltsville, MD USA
Bethlehem University in the Holy Land
E-mail: info@bethlehem.edu
Phone: +972-2-274-1241
Fax: +972-2-274-4440
Bethlehem, Palestine